|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
97,871,000 |
Market
Cap: |
888.67(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.66 - $22.03 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 20.2 |
Insider 6 Months : 20.2 |
Insider 3/6 Months : 40.8 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,350,000 |
1,350,000 |
1,350,000 |
7,872,717 |
Total Buy Value |
$20,722,500 |
$20,722,500 |
$20,722,500 |
$80,714,496 |
Total People Bought |
1 |
1 |
1 |
2 |
Total Buy Transactions |
1 |
1 |
1 |
6 |
Total Shares Sold |
57,195 |
107,195 |
154,628 |
206,908 |
Total Sell Value |
$623,326 |
$1,183,326 |
$2,078,063 |
$2,842,845 |
Total People Sold |
1 |
1 |
4 |
5 |
Total Sell Transactions |
2 |
3 |
7 |
15 |
End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hayden Michael R |
|
|
2023-03-28 |
4 |
B |
$16.15 |
$993,839 |
I/I |
61,538 |
61,538 |
0.01 |
-5% |
|
Shah Rajeev M. |
Director |
|
2023-03-24 |
4 |
B |
$16.25 |
$39,999,993 |
I/I |
2,461,538 |
11,081,584 |
2.25 |
-1% |
|
Martins Ryan |
Chief Financial Officer |
|
2023-03-23 |
4 |
AS |
$16.11 |
$80,550 |
D/D |
(5,000) |
53,578 |
|
-8% |
|
Palekar Rohan |
Chief Executive Officer |
|
2023-03-23 |
4 |
AS |
$16.00 |
$240,000 |
D/D |
(15,000) |
269,080 |
|
-8% |
|
Atkinson Edward Morrow Iii |
Director |
|
2023-03-01 |
4 |
AS |
$13.60 |
$136,000 |
D/D |
(10,000) |
0 |
|
35% |
|
Atkinson Edward Morrow Iii |
Director |
|
2023-03-01 |
4 |
OE |
$4.44 |
$44,400 |
D/D |
10,000 |
10,000 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-21 |
4 |
AS |
$13.89 |
$35,281 |
D/D |
(2,540) |
58,578 |
|
36% |
|
Le-Nguyen Quoc |
See Remarks |
|
2023-02-17 |
4 |
D |
$13.97 |
$29,896 |
D/D |
(2,140) |
91,179 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-17 |
4 |
D |
$13.97 |
$24,448 |
D/D |
(1,750) |
61,118 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2023-02-17 |
4 |
D |
$13.97 |
$29,714 |
D/D |
(2,127) |
94,671 |
|
- |
|
Palekar Rohan |
Chief Executive Officer |
|
2023-02-17 |
4 |
D |
$13.97 |
$87,718 |
D/D |
(6,279) |
284,072 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
93,319 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
62,868 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
96,798 |
|
- |
|
Palekar Rohan |
Chief Executive Officer |
|
2023-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
290,351 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-08 |
4 |
AS |
$14.41 |
$21,327 |
D/D |
(1,480) |
32,868 |
|
36% |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-05 |
4 |
D |
$13.24 |
$7,838 |
D/D |
(592) |
34,348 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2023-02-05 |
4 |
D |
$13.24 |
$18,006 |
D/D |
(1,360) |
66,798 |
|
- |
|
Palekar Rohan |
Chief Executive Officer |
|
2023-02-05 |
4 |
D |
$13.24 |
$53,993 |
D/D |
(4,078) |
215,351 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2023-02-05 |
4 |
D |
$13.24 |
$18,404 |
D/D |
(1,390) |
63,319 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-03 |
4 |
AS |
$12.70 |
$46,848 |
D/D |
(3,592) |
35,368 |
|
62% |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-03 |
4 |
OE |
$3.11 |
$9,330 |
D/D |
3,000 |
38,960 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2023-02-01 |
4 |
D |
$12.05 |
$8,375 |
D/D |
(695) |
64,709 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2023-02-01 |
4 |
D |
$12.05 |
$4,916 |
D/D |
(408) |
35,960 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2023-02-01 |
4 |
D |
$12.05 |
$8,194 |
D/D |
(680) |
68,158 |
|
- |
|
89 Records found
|
|
Page 1 of 4 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|